were significantly associated with survival in glioblastoma. Two SNPs, rs147960238 in CD163 (p = 2.2 × 10 −5 ) and rs17138945 in MET (p = 5.6 × 10 −5 ) were significantly associated with survival of patients with lower-grade glioma. However, these associations were not confirmed in an independent analysis of 563 lower-grade glioma cases from the University of California at San Francisco Adult Glioma Study (p = 0.65 and p = 0.41, respectively). The results of this study do not support a role for inherited polymorphisms in myeloid-associated genes in affecting survival of patients diagnosed with glioblastoma or lower-grade glioma.
Introduction
Gliomas, which account for approximately 75% of primary malignant brain tumors [1] , exist in a dynamic microenvironment that influences tumor development and ultimately patient survival. Although gliomas are highly infiltrated by immune cells of the myeloid lineage including microglia, macrophages, and myeloid-derived suppressor cells (MDSCs; collectively, glioma-associated myeloid cells), these cells have been shown to adopt immunosuppressive and tumor-supportive phenotypes in response to tumorsecreted signals [2] [3] [4] [5] . Furthermore, the degree of myeloidderived cell infiltration has been shown to correlate with glioma grade in human specimens and survival in mouse models of glioma [6] [7] [8] . Given these observations, we hypothesized that germline polymorphisms in genes central to the function of glioma-associated myeloid cells may be associated with the prognosis of patients with glioblastoma or lower-grade glioma.
Materials and methods

Study subjects and data collection
Participants in the discovery population for this study included 992 adult glioma patients of Caucasian ethnicity (ICD-O-3 codes 9380-9340) diagnosed and treated at The University of Texas MD Anderson Cancer Center (MD Anderson) in Houston, TX from 1992 to 2008 [9, 10] . Treatment and survival data (dates of death or last contact) were collected retrospectively from medical record review through August 2016, and dates of death were confirmed by querying the Social Security Death Index (a database created from the United States Social Security Administration's Death Master File). Glioblastoma patients were restricted to those who received both chemotherapy and radiotherapy. The study was approved by the Institutional Review Boards of both MD Anderson and Baylor College of Medicine, and written informed consent was obtained from each participant. An independent population of 563 patients with lower-grade glioma who were included in the University of California at San Francisco Adult Glioma Study [11] served as a validation set for this analysis.
Selection of genes, SNPs, and genotyping assays
We identified genes related to the biology of glioma-associated myeloid cells for analysis in this study. In total, 91 genes were selected based on a systematic review of the literature by our research group and included those encoding transcription factors, cytokines and chemokines, receptors, enzymes, and other genes as previously described for which genotyping data were available [12] (Table 1) . Genotyping for the discovery population was conducted using the Illumina Human 610-Quad Bead Chip platform, and genotype imputation was performed to increase genomic resolution, as previously described [9, 11] . A total of 2040 study population-specific haplotype-tagging SNPs (r 2 ≥ 0.8) with minor allele frequency (MAF) ≥1% were identified using Haploview Tagger software [13] in the 91 gene regions, plus 5 kb upstream of the selected genes.
Statistical methods
Survival time was defined as the time between pathological diagnosis and date of death, if known, or date of last contact (patients in the latter group were censored as of the date of last contact). We computed hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazards regression for individual SNPs of interest under an additive allelic model for glioblastoma and lower-grade glioma patient groups with p values determined by the Wald method. Proportional hazards assumptions were checked for each variable via examination of Schoenfeld residuals and log-log survival plots; assumptions were met for all variables except for surgery among glioblastoma patients, which was remedied by performing Cox regression stratified by surgery type to allow for different baseline hazards. Glioblastoma models were adjusted for age and sex, whereas lower-grade glioma models were adjusted for age, sex, extent of surgery (gross total/partial/ biopsy), chemotherapy (yes/no), and radiotherapy (yes/ no). Gene-based tests were performed using the CoxKM method [14] , and all analyses were performed using R (https://www.r-project.org). Adjustment for multiple comparisons was performed by calculation of False Discovery Rate (FDR)-adjusted p values according to the method of Benjamini and Hochberg [15] . 
Results
Discovery set patient characteristics
Characteristics for the glioblastoma (WHO grade IV) and lower-grade glioma (WHO grade II-III) discovery set populations are presented in Tables 2 and 3 , respectively. As of August 2016, a date of death was known for 458 of 511 (89.6%) glioblastoma patients and 299 of 481 (62.2%) lowergrade glioma patients, and the median survival times (MSTs) were 1.6 and 6.8 years, respectively. Approximately twothirds of patients in both groups were male, and the mean age at diagnosis was 52.6 years for glioblastoma subjects and 40.4 years for lower-grade glioma subjects. At the univariate level, sex, age at diagnosis, and extent of surgery were each statistically significantly-associated with survival of glioblastoma, whereas age at diagnosis, tumor grade, tumor histology, extent of surgery, and treatment with radiotherapy and chemotherapy were each associated with survival of lower-grade glioma.
Myeloid-associated gene variants and survival
Haplotype-tagging SNPs (n = 2040) in 91 myeloid-associated genes were evaluated for association with glioma survival. All individual SNP associations with survival in patients with glioblastoma and lower-grade glioma are illustrated in Fig. 1 , and the results for the top-associated SNPs in each glioma subtype are presented in Table 4 . The SNP most strongly associated with survival of glioblastoma patients was rs147177288 in NFKB1 (HR = 2.53; 95% CI 1.47-4.37; p = 8.7 × 10 −4 ); however, this association was not significant after adjustment for multiple testing (FDR-adjusted p = 0.73). In the lower-grade glioma analysis, five SNPs were associated with survival at p < 0.001, two of which remained significant after adjustment for multiple comparisons (FDR-adjusted p < 0.10). The results indicated inferior survival for carriers of the C allele at rs147960238 in CD163 (HR = 5.47, 95% CI 2.49-11.99, p = 2.2 × 10 −5 , FDR-adjusted p = 0.046) and for carriers of the G allele at rs17138945 in MET (HR = 2.27, 95% CI 1.52-3.38, p = 5.6 × 10 −5 , FDRadjusted p = 0.057). In gene-based analyses, the strongest associations with survival in patients with glioblastoma and lower-grade glioma were observed for IL6 (p = 0.013) and STAT3 (p = 0.034), respectively; however, neither was significant after correction for the 91 genes analyzed.
Replication results
Associations between rs147960238 and rs17138945 and survival of lower-grade glioma were evaluated in an independent cohort of 563 patients with grade II and grade III glioma participating in the University of California at San Francisco Adult Glioma Study [11] . The median survival time for this population was 9.6 years, and dates of death were recorded for 274 (48.7%) of the subjects. The median age at diagnosis was 44 years, and 57% of subjects were male. The distribution of tumor histologies did not differ significantly from those in the discovery set (p = 0.20). Minor allele frequencies for rs147960238 (0.014) and rs17138945 (0.042) were consistent with the discovery set population. When tested under the same model as employed in the discovery analysis, these variants were not associated with lower-grade glioma survival (rs147960238: HR = 0.82, 95% CI 0.36-1.88, p = 0.65; rs17138945: HR = 0.84; 95% CI 0.56-1.27; p = 0.41). 
Discussion
Gliomas have been shown to inhibit effective antitumor immune responses via a variety of local and systemic immunosuppressive mechanisms [16, 17] . Myeloidderived immune cells including microglia, macrophages, and MDSCs are potent mediators of this immunosuppressive activity [18] [19] [20] . In this study, we sought to test the specific hypothesis that polymorphisms in genes involved in the immunosuppressive behavior of glioma-associated myeloid cells are associated with survival of patients with glioblastoma or lower-grade glioma. An analysis of 511 glioblastoma patients did not provide support for our hypothesis at the individual SNP-or gene-level. In an analysis of 481 lower-grade glioma patients, rs147960238, which is located in the 10th intron of CD163, and rs17138945, which is located in the 2nd intron of MET, were significantly associated with survival. CD163 is a hemoglobin/haptoglobin complex receptor that is expressed on macrophages and microglia and may play a role in macrophage-mediated anti-inflammatory responses [21, 22] . MET is a receptor tyrosine kinase and proto-oncogene that is also involved in the expansion of MDSC populations [23] . The associations observed at these genes were not reproduced in an independent analysis of 563 patients with lower-grade glioma who participated in the University of California at San Francisco Adult Glioma Study. It is plausible that detection of these effects in the replication set was hindered by differences between study populations such as in treatment received or in the underlying molecular subtypes of glioma. We were unable to control for treatment variables with greater specificity due to limitations of the data available. However, the associations observed with the low-frequency variants at rs147960238 and rs17138945 in the discovery population may also be attributable to chance, highlighting the importance of independent validation in studies of this nature.
Taken together, although the immunosuppressive effects of glioma-associated myeloid cells are well-documented, the results of this study do not support a significant role for --inherited genetic variation in genes governing this behavior in survival of glioma patients. Notably, a similar conclusion was reached in a recent analysis of variants in myeloid-derived suppressor cell pathway genes and survival of ovarian cancer patients [24] . Our study had ≥80% power at α = 0.05/2040 = 2.45 × 10 −5 to detect hazard ratios of at least 1.42 and 1.78 in the glioblastoma analysis and 1.53 and 1.94 in the lower-grade glioma analysis in variants with minor allele frequencies of 40 and 10%, respectively. Thus, it is plausible that associations may exist with smaller effect sizes and/or with rare variants; it is also possible that associations were missed in genes involved in myeloid cell regulation that were not included for analysis in our study. However, this study did not detect reproducible associations between polymorphisms in known myeloid-associated genes and survival in glioma patients, despite sufficient statistical power to detect moderate and large effects.
